The company exhibits severe operational distress with operating margins reaching -666.0% in 2026Q1, reflecting a fundamental inability to scale revenue beyond a negligible $2.7K quarterly figure.
| Sales/Revenue | 16.57K | 14.82K | 34.89K | 17.07K | 950 | 901 | 0 |
| Revenue Growth % | -16.77% | -57.51% | 104.45% | 1696.32% | 5.44% | - | - |
| Cost of Goods Sold | 94.65K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -78.09K | 14.82K | 34.89K | 17.07K | 950 | 901 | 0 |
| Gross Margin % | -471.4% | 100% | 100% | 100% | 100% | 100% | - |
| Gross Profit Growth % | - | -57.51% | 104.45% | 1696.32% | 5.44% | - | - |
| Operating Expenses | 6.56M | 6.5M | 8.4M | 7.26M | 4.55M | 621.35K | 609.16K |
| OpEx % of Revenue | - | 43837.46% | 24077.86% | 42540.43% | 478884.32% | 68962.15% | - |
| Selling, General & Admin | 6.03M | 5.79M | 8.15M | 7.1M | 4.49M | 573.88K | 597K |
| SG&A % of Revenue | - | 39072.23% | 23367.91% | 41577.26% | 472942.42% | 63693.78% | - |
| Research & Development | 768.79K | 641.21K | 227.97K | 145.18K | 40.45K | 31.47K | 1.5K |
| R&D % of Revenue | - | 4325.21% | 653.38% | 850.76% | 4257.68% | 3492.56% | - |
| Other Operating Expenses | -240.91K | 65.23K | 19.74K | 19.18K | 16K | 16K | 10.67K |
| Operating Income | -6.64M | -6.48M | -8.37M | -7.24M | -4.55M | -620.45K | -609.16K |
| Operating Margin % | -40074.58% | -43737.46% | -23977.86% | -42440.43% | -478784.32% | -68862.15% | - |
| Operating Income Growth % | - | 22.49% | -15.51% | -59.23% | -633.09% | -1.85% | - |
| EBITDA | -6.27M | -6.09M | -8.09M | -7.13M | -4.53M | -604.45K | -598.5K |
| EBITDA Margin % | -37856.29% | -41051.94% | -23185.82% | -41786.34% | -477100.11% | -67086.35% | - |
| EBITDA Growth % | -14.75% | 24.77% | -13.44% | -57.33% | -649.85% | -0.99% | - |
| D&A (Non-Cash Add-back) | 367.46K | 398.13K | 276.35K | 111.62K | 16K | 16K | 10.67K |
| EBIT | -6.64M | -6.48M | -8.36M | -1.64M | -4.66M | -620.45K | -609.16K |
| Net Interest Income | -12.91K | -14.09K | -17.58K | -6.73M | 0 | 0 | 0 |
| Interest Income | 643 | 712 | 1.06K | 1.07K | 0 | 0 | 0 |
| Interest Expense | 13.55K | 14.8K | 18.64K | 6.74M | 0 | 0 | 0 |
| Other Income/Expense | -12.91K | -14.09K | -17.58K | -1.13M | -112.53K | 0 | 4K |
| Pretax Income | -6.65M | -6.5M | -8.38M | -8.38M | -4.66M | -620.45K | -605.16K |
| Pretax Margin % | -40152.5% | -43832.49% | -24028.24% | -49087.81% | -490630% | -68862.15% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -6.65M | -6.5M | -8.38M | -8.38M | -4.66M | -620.45K | -605.16K |
| Net Margin % | -40152.5% | -43832.49% | -24028.24% | -49087.81% | -490630% | -68862.15% | - |
| Net Income Growth % | -13.6% | 22.49% | -0.08% | -79.72% | -651.23% | -2.53% | - |
| Net Income (Continuing) | -6.65M | -6.5M | -8.38M | -8.38M | -4.66M | -620.45K | -605.16K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.34 | -3.71 | -9.30 | -19.80 | -45.30 | -1.96 | -0.06 |
| EPS Growth % | -16.87% | 60.11% | 53.03% | 56.29% | -2211.22% | -2981.76% | - |
| EPS (Basic) | - | -3.71 | -9.30 | -19.80 | -45.30 | -1.96 | -0.06 |
| Diluted Shares Outstanding | 2.84M | 1.75M | 26.89M | 422.84K | 3.09M | 317.16K | 9.52M |
| Basic Shares Outstanding | 2.84M | 1.75M | 26.89M | 422.84K | 3.09M | 317.16K | 9.52M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Inability to achieve scale
As reported in recent financial filings, CDIO's quarterly revenue remains negligible, with TTM figures totaling only $14,825, reflecting a persistent inability to gain clinical traction or establish a repeatable sales model for its Epi+Gen CHD diagnostic test within the competitive cardiovascular testing landscape.
The lack of consistent revenue growth suggests that the company's current commercial strategy is failing to penetrate the market or secure necessary insurance reimbursement. Investors should monitor whether the recent volatility in quarterly revenue indicates a fundamental lack of product-market fit or merely the early-stage friction of a nascent diagnostic platform.
Based on the provided income statement data, the company's operating expenses, primarily driven by SG&A and R&D, dwarf the minimal revenue generated, resulting in an unsustainable cost structure that necessitates constant capital infusions to maintain basic laboratory and regulatory operations.
The massive disparity between operating expenses and revenue suggests that the company is currently functioning as an R&D project rather than a commercial entity. Without a significant shift in testing volume, the current expense discipline appears insufficient to prevent continued erosion of the company's limited cash reserves.
While the reported 100% gross margin appears favorable, it is likely an accounting artifact of low volume rather than true pricing power, as the company's operating margins remain deeply negative, consistently exceeding -400% in recent quarters according to the latest financial disclosures.
The 100% gross margin figure warrants skepticism, as it likely excludes the true costs of test processing that are currently buried in operating expenses. A more accurate assessment of profitability would require reclassifying these costs, which would likely reveal a much more strained margin profile than the headline numbers suggest.
Although the income statement reflects a failing commercial enterprise, a non-consensus view suggests the company's value may be tied to its proprietary epigenetic data sets and intellectual property, which could hold strategic option value for larger diagnostic players despite the current lack of sales.
Short-sellers would likely focus on the extreme cash burn and the lack of a clear path to profitability as evidence of an impending liquidity crisis. However, the potential for an M&A exit based on the underlying technology remains a speculative counter-narrative that investors should weigh against the high probability of further equity dilution.
Quick answers to the most common questions about buying CDIO stock.
For fiscal year 2025, Cardio Diagnostics Holdings, Inc. (CDIO) reported total revenue of $0.0M.
Cardio Diagnostics Holdings, Inc. (CDIO) reported a net loss of $6.5M for the fiscal year ending 2025.
Cardio Diagnostics Holdings, Inc. (CDIO) reported an operating income of $-6.5M, resulting in an operating profit margin of -43737.5%. This margin reflects the operational efficiency of the business before interest and taxes.
Cardio Diagnostics Holdings, Inc. (CDIO) generated $0.0M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.